Discovery of protein phosphorylation markers to predict the efficacy of anti-EGFR antibody drugs in colorectal cancer patients

点击翻译按钮获取中文摘要

Anti-EGFR antibody drugs have been approved for metastatic colorectal cancer (mCRC) therapy, but the drugs are ineffective for CRC exhibiting EGF-independent activation of the EGFR signaling pathway. Although a part of the patients with the aberrant EGFR signaling can be detected by the KRAS mutation testing, further improvement of the method detecting the EGFR signaling-aberrant patients is needed. In this study, using colorectal cancer cell lines, we examined whether comprehensive analysis of activation levels of kinases related to the EGFR signaling could potentiate to predict the efficacy of the anti-EGFR drugs. In addition, I found a novel mechanism by which the anti-EGFR drugs inhibit proliferation of CRC cells. This study showed several biomarker candidates to predict the efficiency of the anti-EGFR antibody drugs.